Total research and development (R and D) expenditures at American colleges and universities topped $86 billion in Fiscal Year 2020, according to the most recent Higher Education Research and Development (HERD) Survey, released by the National Science Foundation (NSF) on Monday. The total represents an increase of $2.7 billion (3.3%) over FY 2019.
By Holden Wilen – Reporter December 23, 2021, 01:35pm EST Personal Genome Diagnostics has agreed to be acquired by one of the world’s largest life sciences companies in a deal that could pay up to $575 million.
Baltimore-based PGDx has agreed to sell to Laboratory Corp., of America Holdings, better known as Labcorp. The Burlington, North Carolina-based giant is a leader in medical testing and drug development, and has played a particularly important role during the last year and a half with Covid-19 testing. PGDx specializes in developing in vitro diagnostic (IVD) tests that can be used to analyze the DNA of tumors to diagnose cancer.
Pharmacy Times interviewed Ronald T. Piervincenzi, PhD, the CEO of US Pharmacopeia (USP), on reflections from 2021 and predictions for 2022.
The discussion is the seventh in a video series collaboration between Pharmacy Times and USP that highlights USP’s work to support the pharmacist and discussed USP’s perspective on timely and topical issues in the field.
Personal Genome Diagnostics has agreed to be acquired by one of the world’s largest life sciences companies in a deal that could pay up to $575 million.
Baltimore-based PGDx has agreed to sell to Laboratory Corp., of America Holdings, better known as Labcorp. The Burlington, North Carolina-based giant is a leader in medical testing and drug development, and has played a particularly important role during the last year and a half with Covid-19 testing. PGDx specializes in developing in vitro diagnostic (IVD) tests that can be used to analyze the DNA of tumors to diagnose cancer.
Image: Personal Genome Diagnostics, or PGDx, which is based in Canton, is getting bought by life sciences giant Labcorp. Carley Milligan
As the omicron variant became the dominant strain in the U.S. this week, health care providers are left with fewer options to treat positive COVID-19 patients as most of the existing treatments have been found to be less effective in fighting off the new variant.
Up until recently, the U.S. Department of Health and Human Services (HHS) had been distributing three types of COVID-19 antibody treatments, Regeneron monoclonal antibodies, Eli Lilly’s antibody treatments and GlaxoSmithKline’s sotrovimab monoclonal antibody.
Please join us in welcoming our two newest members of the CLS Board of Directors!
• Vasiliki Anest,Ph.D: serves as Chief Innovation Officer for USC Norris Comprehensive Cancer Center
• Kwame Ulmer: is a venture partner at Wavemaker Three-Sixty Health
Their experience and backgrounds will be invaluable in supporting CLS’s goals to empower the life sciences ecosystem.
Image: https://www.linkedin.com/feed/update/urn:li:activity:6877654463474143232/
ROCKVILLE, MD. (PRWEB) DECEMBER 21, 2021 Data from the First Three Patients Shows Critical Efficacy Markers of the HIV Cure Cell Therapy: Engraftment, Persistence, and Maintained HIV-clearing Functionality of Infused Cells
American Gene Technologies (AGT), a clinical-stage biotechnology company working to cure HIV, announced that it has reached two important milestones for its HIV cure program.
All three patients achieved engraftment of the genetically modified cell product, AGT103-T, and avoided rejection of the infused cells. In addition, patient samples were challenged to determine if their HIV-specific response remained active. All three products demonstrated an active response. These two studies confirm that the patients retained an appropriate concentration of the product and indicate AGT103-T should be able to create an effective immune response against HIV in the absence of antiretroviral treatment (ART).
Located in the heart of Maryland’s Shady Grove Life Sciences Center, 9603 Medical Center Drive has efficient access to all points in Montgomery County via Route 355 and I-270 and is minutes to the Intercounty Connector (Route 200), which connects I-270 to I-95.
Since the beginning of the global pandemic, capital has flowed into the BioCapital Health Region. Billions of dollars from Operation Warp Speed, as well as private venture firms, have poured in to support startups, as well as companies focused on pandemic responses.
Image: Image / Pixabay
Company’s Third Major Acquisition Expands European Presence in Germany; Adds New Electronic Data Capture Tool to Enhance Real World Evidence Research
ROCKVILLE, Md., Dec. 21, 2021 /PRNewswire/ — Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that it has acquired Institut Dr. Schauerte, a CRO headquartered in Munich, Germany. Founded in 1990, Institut Dr. Schauerte is a full-service, technology-oriented CRO that specializes in late-phase, non-interventional, and post-market clinical follow-up studies. It has conducted more than 400 studies across a range of therapeutic areas.
